Ionis Q3 Revenue Rises 55%; Lowers TRYNGOLZA Sales Outlook On Slower Launch; Shares Fall 28%
Ionis Pharmaceuticals (IONS) reported Q3 2026 revenue of $243M, up 55% YoY excluding a prior licensing payment. TRYNGOLZA sales missed expectations, leading to a lowered full-year outlook. DAWNZERA sales grew 18% YoY. The company reaffirmed its 2026 revenue guidance of $875M-$900M but lowered TRYNGOLZA's sales forecast to $50M. Shares fell 28%.
How this was made
The 30-second read
Why it matters
The earnings beat on revenue was outweighed by a significant sales outlook cut, leading to a sharp share decline.
Market read
The guidance cut on a flagship product drives immediate downside risk for IONS and may influence sentiment toward similar RNA‑based therapies.
What to watch
Strong royalty revenue from SPINRAZA and robust DAWNZERA sales may offset the TRYNGOLZA shortfall.
Background
Ionis Pharmaceuticals (IONS) disclosed its Q3 2026 earnings, highlighted revenue growth, and revised guidance for its triglyceride drug TRYNGOLZA.
Ticker impact
Ionis reported Q3 2026 revenue up 55% YoY to $243M and cut full-year TRYNGOLZA sales outlook to $50M, causing a 28% share decline.
likely continued pressure as the market prices in lower TRYNGOLZA revenue and modest guidance.
The earnings release contains fresh revenue numbers and a material downward revision to a key product outlook, which directly moved the stock.
Market effects
Biotech sector may see heightened scrutiny on launch timelines for RNA‑targeted therapies.
U.S. biotech stocks could face short‑term weakness as investors reassess launch risk.
Limited; impact confined to U.S. biotech and partner companies.
Counterpoint
If the slower launch is temporary, the stock may be oversold and could rebound on future data.
Key entities
- companyIonis Pharmaceuticals
Biotech firm developing RNA‑targeted medicines.
- productTRYNGOLZA
Olezarsen for severe hypertriglyceridemia.
